



# FINANCIAL REPORT 2010



TAJ PHARMACEUTICALS LIMITED





**THIS PRESENTATION IS NOT AN ADVERTISEMENT OF SECURITIES IN ANY JURISDICTION.**

**NOT FOR RELEASE, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA OR JAPAN.**

This document includes statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the fact that they do not only relate to historical or current events. Forward-looking statements often use words such as "anticipate", "target", "expect", "estimate", "intend", "expected", "plan", "goal" believe", or other words of similar meaning. By their nature, forward-looking statements involve risk and uncertainty because they relate to future events and circumstances, a number of which are beyond Company's control. As a result, actual future results may differ materially from the plans, goals and expectations set out in these forward-looking statements. Any forward-looking statements made by or on behalf of the Company speak only as at the date of this announcement. Save as required by any applicable laws or regulations, the Company undertakes no obligation publicly to release the results of any revisions to any forward-looking statements in this document that may occur due to any change in its expectations or to reflect events or circumstances after the date of this document. The securities referred to herein have not been and will not be registered under the US Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States or to US persons unless the securities are registered under the Securities Act, or an exemption from the registration requirements of the Securities Act is available. No public offering of the securities will be made in the United States. This communication is being distributed only to and is directed only at (a) persons outside the United Kingdom, (b) persons who have professional experience in matters relating to investments, i.e., investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order"), and (c) high net worth companies, unincorporated associations and other bodies to whom it may otherwise lawfully be communicated in accordance with Article 49 of the Order (all such persons together being referred to as "relevant persons"). The securities are available only to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such securities will be available only to or will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on this communication or any of its contents.



# TAJ PHARMACEUTICALS INDIA



PHARMA BUSINESS



WORLDWIDE

Taj has been consistently launching new products, which includes not only first time launches but also line extensions of existing brands.  
more...

---

**Welcome to the Taj Pharmaceuticals Limited India. We would like to give you an overview of Taj Pharmaceuticals Limited in India: our background, organization, products, core belief and prospects.**

---



## Environmental Stewardship



### A matter of course for Taj Pharmaceuticals

Taj Pharmaceuticals has long been aware that only a financially successful company can be active in environmental and social areas and that financial success only results if it acts in an environmentally and socially responsible manner. In this context, we consider sustainable development to mean a long-term process designed to meet the needs of current and future generations.

Safety and environmental protection are two important invariables amid changing values. Thus, the assurance of safety and environmental protection is not only required by law but constitutes an obligation and at the same time a key success factor in all our business dealings.





## Taj Group “TAJ PHARMA GROUP” AND SUBSIDIARIES HOLDINGS

### COMBINED AND CONSOLIDATED INCOME STATEMENT FOR THE YEAR ENDED MARCH 31, 2010 (in USD\$ and in Millions)

	2010	2009
NET SALES	79 368	59 578
COST OF SALES	(32 410)	(27 353)
GROSS PROFIT	46 958	32 225
SELLING, GENERAL AND ADMINISTRATIVE EXPENSES	(25 013)	(19 529)
NON-RECURRING OPERATING EXPENSES	(1 813)	(35)
OTHER OPERATING INCOME	-	657
OPERATING INCOME	20 132	13 318
NON-OPERATING INCOME (EXPENSES):		
Interest expense	(1 476)	(1 880)
Foreign currency exchange gain/(loss)	(111)	(38)
INCOME BEFORE INCOME TAX EXPENSE	18 545	11 400
Income tax expense	(2 509)	(1 289)
NET INCOME	<u>16 036</u>	<u>10 111</u>

Taj Pharmaceuticals Limited (the "Company") believes that the information included in the Investor Relations section of this website was correct at the time it was added to the website. However, the Company expressly disclaims any duty to update the information on the website and makes no representation or warranty as to accuracy and completeness of the contents of this Investors Relations section of the website or any other section of the website. Access to and use of the information on this website is at the user's own risk. The Company assumes no responsibility for any errors or omissions in the content of this website and disclaims any liability for damages of any kind (whether direct, consequential or punitive) arising out of the use of this website or the information contained on the website or on links to or from this website.

The Investor Relations section of this website contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. All statements other than statements of historical facts, included on this website regarding the Company's strategy, expected future financial position, results of operations, cash flows, financing plans, discovery and development of products, strategic alliances, competitive position, plans and objectives of management are forward-looking statements. Words such as "anticipate," "believe," "estimate," "expect," "intend," "plan," "will" and other similar expressions help identify forward-looking statements, although not all forward-looking statements contain these identifying words. In particular, any statements regarding the Company's financial results and outlook, the continued implementation of the Company's strategic plan, the development of the Company's pipeline, the commencement of Phase 3 clinical trials for Puricase (pegloticase) are forward-looking statements. These forward-looking statements involve substantial risks and uncertainties and are based on current expectations, assumptions, estimates and projections about the Company's business and the biopharmaceutical and specialty pharmaceutical industries in which the Company operates. Such risks and uncertainties include, but are not limited to, the delay or failure in developing Puricase (pegloticase) and other product candidates; difficulties of expanding the Company's product portfolio through in-licensing or acquisition; not being able to manufacture commercial quantities of our products; not gaining market acceptance sufficient to justify development and commercialization costs if our products are approved for marketing; introduction of generic competition for API; fluctuations in buying patterns of wholesalers; potential future returns of API or other products; the Company continuing to incur substantial net losses for the foreseeable future; difficulties in obtaining financing; potential development of alternative technologies or more effective products by competitors; reliance on third-parties to manufacture, market and distribute many of the Company's products; risks of maintaining protection for the Company's intellectual property; risks of an adverse determination in any future intellectual property litigation; and risks associated with stringent government regulation of the biopharmaceutical and specialty pharmaceutical industries and other factors set forth more fully in certain reports filed with the Securities and Exchange Commission, to which investors are referred for further information. The Company may not actually achieve the plans, intentions or expectations disclosed in its forward-looking statements, and you should not place undue reliance on the Company's forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that the Company makes. The Company's forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments that the Company may make. The Company does not have a policy of updating or revising forward-looking statements and assumes no obligation to update any forward-looking statements.

## Taj Group “TAJ PHARMA GROUP” AND SUBSIDIARIES HOLDINGS

### COMBINED AND CONSOLIDATED BALANCE SHEET AT MARCH 31, 2010 (in USD\$ and in Millions)

	2010	2009
<b>ASSETS</b>		
NON-CURRENT ASSETS:		
Property, plant & equipment, net	23 651	25 138
Intangible assets, net	11 889	11 537
Total non-current assets	<u>35 540</u>	<u>36 675</u>
CURRENT ASSETS:		
Inventories	13 644	9 946
Accounts receivable	34 569	20 385
Receivables from related parties	3 737	9 675
Other receivables and prepaid expenses	6 115	5 478
Cash	314	41
Total current assets	<u>58 379</u>	<u>45 525</u>
<b>TOTAL ASSETS</b>	<b><u>93 919</u></b>	<b><u>82 200</u></b>
<b>LIABILITIES AND SHAREHOLDERS' EQUITY</b>		
SHAREHOLDERS' EQUITY:		
Share capital	1	1
Retained earnings	62 193	48 114
Total shareholders' equity	<u>62 194</u>	<u>48 115</u>
LONG-TERM LIABILITIES:		
Long-term borrowings	11 233	7 208
Deferred taxation	1 797	2 684
Long-term portion of finance lease payable	48	52
Total long-term liabilities	<u>13 078</u>	<u>9 944</u>
CURRENT LIABILITIES:		
Short-term borrowings and current portion of long-term borrowings	2 756	11 238
Accounts payable	6 599	4 752
Other payables and accrued expenses	6 964	4 206
Current portion of finance lease payable	141	267
Payables to related parties	2 187	3 678
Total current liabilities	<u>18 647</u>	<u>24 141</u>
<b>TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY</b>	<b><u>93 919</u></b>	<b><u>82 200</u></b>

---

## Taj Group “TAJ PHARMA GROUP” AND SUBSIDIARIES HOLDINGS

### COMBINED AND CONSOLIDATED STATEMENT OF CASH FLOWS FOR THE YEAR ENDED MARCH 31, 2010 (in USD\$ and in Millions)

	2010	2009
<b>OPERATING ACTIVITIES:</b>		
Income before income tax	18 545	11 400
Adjustments to reconcile net income to net cash used in operating activities:		
Depreciation and amortization	2 051	3 063
Loss on disposal of property, plant and equipment	206	57
Provision for doubtful receivables	(501)	571
Foreign exchange (gain) loss on financing and investing activities	111	38
Write off of third party loan	946	-
Interest expense	1 476	1 880
Operating cash flow before working capital changes	<u>22 834</u>	<u>17 009</u>
Increase in inventories	(3 697)	(776)
Increase in accounts receivable	(13 683)	(5 394)
Increase in receivables from related parties	(540)	(539)
Increase in other receivables and prepaids	(1 583)	(945)
Increase in accounts payable	995	2 703
Decrease in payables from related parties	(256)	(178)
Increase in other payables and accruals	5 323	2 736
Cash flows from operations	<u>9 393</u>	<u>14 616</u>
Income taxes paid	(1 768)	(950)
Interest paid	<u>(4 013)</u>	<u>(2 521)</u>
Net cash inflow from operating activities	<u>3 612</u>	<u>11 145</u>
<b>INVESTING ACTIVITIES:</b>		
Purchase of property, plant, equipment	(1 869)	(3 444)
Purchase of intangible assets	(1 088)	(456)
Purchase of equity interest in subsidiaries	-	(222)
Net cash outflow from investing activities	<u>(2 957)</u>	<u>(4 122)</u>
<b>FINANCING ACTIVITIES:</b>		
Repayment of/proceeds from borrowings, net	(3 794)	1 275
Proceeds from/repayment of borrowings from related parties, net	<u>5 043</u>	<u>(10 426)</u>
Net cash inflow(outflow) from financing activities	<u>1 249</u>	<u>(9 151)</u>
Effect of translation on cash flows	(1 631)	2 039
NET INCREASE (DECREASE) IN CASH	273	(89)
CASH, beginning of period	<u>41</u>	<u>130</u>
CASH, end of period	<u>314</u>	<u>41</u>



## Taj Group “TAJ PHARMA GROUP” AND SUBSIDIARIES HOLDINGS

### COMBINED AND CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS’ EQUITY FOR THE YEAR ENDED MARCH 31, 2010 (in USD\$ and in Millions)

	Share Capital	Retained Earnings	Total Shareholders' Equity
<b>Balance at MARCH 1, 2008</b>	<b>1</b>	<b>35 444</b>	<b>35 445</b>
Net income	-	10 111	10 111
Currency translation	-	2 559	2 559
<b>Balance at MARCH 31, 2009</b>	<b>1</b>	<b>48 114</b>	<b>48 115</b>
Net income	-	16 036	16 036
Currency translation	-	(1 958)	(1 958)
<b>Balance at MARCH 31, 2010</b>	<b>1</b>	<b>62 192</b>	<b>62 193</b>



Taj Pharmaceuticals Limited (the "Company") believes that the information included in the Investor Relations section of this website was correct at the time it was added to the website. However, the Company expressly disclaims any duty to update the information on the website and makes no representation or warranty as to accuracy and completeness of the contents of this Investors Relations section of the website or any other section of the website. Access to and use of the information on this website is at the user's own risk. The Company assumes no responsibility for any errors or omissions in the content of this website and disclaims any liability for damages of any kind (whether direct, consequential or punitive) arising out of the use of this website or the information contained on the website or on links to or from this website.

The Investor Relations section of this website contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. All statements other than statements of historical facts, included on this website regarding the Company's strategy, expected future financial position, results of operations, cash flows, financing plans, discovery and development of products, strategic alliances, competitive position, plans and objectives of management are forward-looking statements. Words such as "anticipate," "believe," "estimate," "expect," "intend," "plan," "will" and other similar expressions help identify forward-looking statements, although not all forward-looking statements contain these identifying words. In particular, any statements regarding the Company's financial results and outlook, the continued implementation of the Company's strategic plan, the development of the Company's pipeline, the commencement of Phase 3 clinical trials for Puricase (pegloticase) are forward-looking statements. These forward-looking statements involve substantial risks and uncertainties and are based on current expectations, assumptions, estimates and projections about the Company's business and the biopharmaceutical and specialty pharmaceutical industries in which the Company operates. Such risks and uncertainties include, but are not limited to, the delay or failure in developing Puricase (pegloticase) and other product candidates; difficulties of expanding the Company's product portfolio through in-licensing or acquisition; not being able to manufacture commercial quantities of our products; not gaining market acceptance sufficient to justify development and commercialization costs if our products are approved for marketing; introduction of generic competition for API; fluctuations in buying patterns of wholesalers; potential future returns of API or other products; the Company continuing to incur substantial net losses for the foreseeable future; difficulties in obtaining financing; potential development of alternative technologies or more effective products by competitors; reliance on third-parties to manufacture, market and distribute many of the Company's products; risks of maintaining protection for the Company's intellectual property; risks of an adverse determination in any future intellectual property litigation; and risks associated with stringent government regulation of the biopharmaceutical and specialty pharmaceutical industries and other factors set forth more fully in certain reports filed with the Securities and Exchange Commission, to which investors are referred for further information. The Company may not actually achieve the plans, intentions or expectations disclosed in its forward-looking statements, and you should not place undue reliance on the Company's forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that the Company makes. The Company's forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments that the Company may make. The Company does not have a policy of updating or revising forward-looking statements and assumes no obligation to update any forward-looking statements.

## About Taj Pharmaceutical Limited

Taj Pharmaceuticals Limited is a pharmaceutical company founded and based in India. The company manufacturers pharmaceutical formulations and API for India and other countries of world. The company was established in 1995 as an enterprise and in 2004 became a public limited company. As per Mumbai pharmaxil and Chemixil association the company manufacturers and exports to countries like Albania, Argentina, Austria, Chile and Iraq. In 1995 pharmaceuticals wing only has a schedule M certification for pharmaceuticals products manufacturing in India. Taj Pharmaceuticals established its manufacturing unit in Gujarat because of government policies in 1999 with WHO / GMP licence. The company in 2003 revived all the old manufacturing units and approached the FDA Gujarat for 4000 new pharmaceuticals drug permissions for the first time in India.

According to the Indian Trade Mark the company owns about 450 brands and 4600 generic manufacturing permissions in India. According to the export data analysis the company was the largest exporter of generic medicines to the Europe and Middle East countries.

[www.tajpharma.com](http://www.tajpharma.com)

The company medicines are present in France, Georgia, Egypt and CIF countries.



Note: This site contains medical information that is intended for doctors or medical practitioner only and is not meant to substitute for the advice provided by a medical professional. Always consult a physician if you have health concerns. Use and access of this site is subject to the terms and conditions as set out in our Privacy Policy and Terms of Use.  
 © Copyright 2011 Taj Pharma Group (India). All rights reserved.



Note: This site contains medical information that is intended for doctors or medical practitioner only and is not meant to substitute for the advice provided by a medical professional. Always consult a physician if you have health concerns. Use and access of this site is subject to the terms and conditions as set out in our Privacy Policy and Terms of Use.  
 © Copyright 2011 Taj Pharma Group (India). All rights reserved.

Taj Pharmaceuticals Limited (the "Company") believes that the information included in the Investor Relations section of this website was correct at the time it was added to the website. However, the Company expressly disclaims any duty to update the information on the website and makes no representation or warranty as to accuracy and completeness of the contents of this Investors Relations section of the website or any other section of the website. Access to and use of the information on this website is at the user's own risk. The Company assumes no responsibility for any errors or omissions in the content of this website and disclaims any liability for damages of any kind (whether direct, consequential or punitive) arising out of the use of this website or the information contained on the website or on links to or from this website.

The Investor Relations section of this website contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. All statements other than statements of historical facts, included on this website regarding the Company's strategy, expected future financial position, results of operations, cash flows, financing plans, discovery and development of products, strategic alliances, competitive position, plans and objectives of management are forward-looking statements. Words such as "anticipate," "believe," "estimate," "expect," "intend," "plan," "will" and other similar expressions help identify forward-looking statements, although not all forward-looking statements contain these identifying words. In particular, any statements regarding the Company's financial results and outlook, the continued implementation of the Company's strategic plan, the development of the Company's pipeline, the commencement of Phase 3 clinical trials for Puricase (pegloticase) are forward-looking statements. These forward-looking statements involve substantial risks and uncertainties and are based on current expectations, assumptions, estimates and projections about the Company's business and the biopharmaceutical and specialty pharmaceutical industries in which the Company operates. Such risks and uncertainties include, but are not limited to, the delay or failure in developing Puricase (pegloticase) and other product candidates; difficulties of expanding the Company's product portfolio through in-licensing or acquisition; not being able to manufacture commercial quantities of our products; not gaining market acceptance sufficient to justify development and commercialization costs if our products are approved for marketing; introduction of generic competition for API; fluctuations in buying patterns of wholesalers; potential future returns of API or other products; the Company continuing to incur substantial net losses for the foreseeable future; difficulties in obtaining financing; potential development of alternative technologies or more effective products by competitors; reliance on third-parties to manufacture, market and distribute many of the Company's products; risks of maintaining protection for the Company's intellectual property; risks of an adverse determination in any future intellectual property litigation; and risks associated with stringent government regulation of the biopharmaceutical and specialty pharmaceutical industries and other factors set forth more fully in certain reports filed with the Securities and Exchange Commission, to which investors are referred for further information. The Company may not actually achieve the plans, intentions or expectations disclosed in its forward-looking statements, and you should not place undue reliance on the Company's forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that the Company makes. The Company's forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments that the Company may make. The Company does not have a policy of updating or revising forward-looking statements and assumes no obligation to update any forward-looking statements.



## TAJ PHARMA GROUP

### Taj Pharmaceuticals Limited

[TAJ GROUP]



#### TAJ PHARMACEUTICALS LIMITED

تاج ناریا سینٹ مس ی.

U.S.- F.D.A. Standards

cGMP & W.H.O Certified

"Working for healthier India"

Regd. Off.: 434, Laxmi Plaza, Laxmi Ind. Estate, New Link Road, Andheri (W), Mumbai - 400 053.

Tel.: 91-22-2637 4592/93, 30601000 Mob.: 09930407744 Fax : 91-22-26341274

CONTACT US

**Factory: UNIT-I**

Plot No. - 1019, Vill. - Sarigam, G.I.D.C. ,  
Road No. 10, Dist. - Valsad, State of Gujarat. Pin Code - 396142

**Factory: UNIT-II**

Vill. Kalgam, Tal. Umargaon, costal highway road,  
State of Gujarat. India

Web.: [www.tajpharmaceuticals.com](http://www.tajpharmaceuticals.com)  
[www.tajfordoctors.co.in](http://www.tajfordoctors.co.in)

E-mail : tajgroup@tajpharma.com/ tajpharma@rediffmail.com



#### TAJ PHARMACEUTICALS LIMITED

"Working for healthier India"

The contents and design of this website, including Authority logos, are the property of the Taj Pharmaceuticals Limited India, and are protected under copyright law and international treaty.

All rights reserved. Except under the conditions described in the Copyright Act 1968 and subsequent amendments, no part of this website may be reproduced or communicated by any process without prior permission in writing from



Copyright © 2004-2011 Taj Pharmaceuticals Limited. All rights reserved. Legal Notice

The products discussed herein may have different product labeling in different countries. The product information provided in this site is intended only for the residents of India.